CompletedPhase 3

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

France166 participantsStarted 2006-10

Plain-language summary

The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients. Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment (irbesartan or placebo) during two years. The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age between 18 and 75 years * liver biopsy performed (less 18 month before inclusion), fibrosis score F2,F3 or F3+ in Metavir classification, * patients without antiviral therapy * contraindication to anti viral treatment * non responders or relapsers patients to past antiviral treatment Exclusion Criteria: * hepatocellular carcinoma * HIV * alcool abuser * cirrhosis * anti-fibrotic treatment * pregnancy or breast feeding

What they're measuring

Assessment of liver fibrosis changes by measurement of area of porto-septal fibrosis (morphometry)at M24

Timeframe: at M24

Trial details

NCT IDNCT00265642

SponsorANRS, Emerging Infectious Diseases

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2013-04

View on ClinicalTrials.gov More Hepatitis C, Chronic trials